NRIX
NASDAQ · Biotechnology
Nurix Therapeutics Inc
$15.15
+0.31 (+2.09%)
Financial Highlights (FY 2026)
Revenue
106.32M
Net Income
-334,795,136
Gross Margin
—
Profit Margin
-314.9%
Rev Growth
+29.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -340.2% | -306.1% | -10.3% | -11.1% |
| Profit Margin | -314.9% | -299.2% | -10.4% | -12.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 106.32M | 82.07M | 234.23M | 200.40M |
| Gross Profit | — | — | 110.64M | 94.65M |
| Operating Income | -361,648,791 | -251,261,318 | -24,140,455 | -22,266,939 |
| Net Income | -334,795,136 | -232,604,309 | -24,379,697 | -25,365,756 |
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -340.2% | -306.1% | -10.3% | -11.1% |
| Profit Margin | -314.9% | -299.2% | -10.4% | -12.7% |
| Rev Growth | +29.5% | +29.5% | +16.3% | -7.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 737.03M | 760.17M |
| Total Equity | — | — | 1.16B | 1.03B |
| D/E Ratio | — | — | 0.64 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -350,583,633 | -257,105,489 | -31,389,191 | -26,544,777 |
| Free Cash Flow | — | — | -25,443,977 | -21,239,062 |